Stockscreener 앱 받기
2.58
0.39%
0.01
전일 마감가:
$2.57
열려 있는:
$2.57
하루 거래량:
526.58K
Relative Volume:
0.57
시가총액:
$111.22M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
-1.157
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
+1.57%
1개월 성능:
+15.70%
6개월 성능:
+68.63%
1년 성능:
+101.56%
1일 변동 폭
$2.56
$2.59
1주일 범위
$2.54
$2.605
52주 변동 폭
$0.89
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
2.58 | 110.79M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 개시 | CapitalOne | Overweight |
| 2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-17 | 재개 | Goldman | Buy |
| 2021-09-23 | 개시 | Stifel | Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2021-06-28 | 개시 | Guggenheim | Buy |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2020-10-28 | 개시 | Northland Capital | Outperform |
| 2020-07-14 | 개시 | Cowen | Outperform |
| 2020-07-14 | 개시 | Goldman | Neutral |
| 2020-07-14 | 개시 | Morgan Stanley | Overweight |
| 2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics (RPTX) Shareholders Approve Acquisition by X - GuruFocus
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics - TipRanks
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - marketscreener.com
Bank Watch: Is Repare Therapeutics Inc stock heavily shorted2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update - MarketBeat
Update Report: Is Repare Therapeutics Inc stock heavily shorted2025 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4%Here's Why - MarketBeat
Levels Update: Is Repare Therapeutics Inc. stock a top pick in earnings season2025 Sector Review & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Opening: Will Repare Therapeutics Inc stock attract ESG investorsMarket Sentiment Summary & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Insider Trends: Why Repare Therapeutics Inc. stock is in analyst buy zonePortfolio Update Report & Capital Efficient Trading Techniques - Bộ Nội Vụ
Published on: 2026-01-13 02:16:07 - baoquankhu1.vn
What catalysts could drive Repare Therapeutics Inc. stock higherTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Oklahoma City NewsThe OklahomanRepare Therapeutics Inc.Common Shares (Nasdaq:RPTX) Stock Quote - FinancialContent
Is Repare Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Review & Risk Managed Trade Strategies - Улправда
Can Repare Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Will Repare Therapeutics Inc. stock benefit from commodity prices2025 Big Picture & Momentum Based Trading Signals - ulpravda.ru
Repare Therapeutics sells RP-3467 cancer program assets to Gilead for up to $30 million - MSN
Can Repare Therapeutics Inc. stock double in next 5 yearsVolatility Adjusted Trading & Learn to Trade with Real-Time Feedback - Улправда
Repare Therapeutics Inc.Common Shares (NQ: RPTX - FinancialContent
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
PYXS,RPTX Dividends - Finviz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Black Hills Pioneer
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout - TipRanks
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Repare Therapeutics Inc 주식 (RPTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 12 '25 |
Sale |
1.14 |
5,611 |
6,397 |
80,297 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 12 '25 |
Sale |
1.14 |
6,884 |
7,848 |
54,786 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 12 '25 |
Sale |
1.14 |
21,179 |
24,144 |
124,394 |
4.73%
0.92%
자본화:
|
볼륨(24시간):